KLP Kapitalforvaltning AS Invests $15.88 Million in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

KLP Kapitalforvaltning AS bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 38,400 shares of the company’s stock, valued at approximately $15,876,000.

Other institutional investors have also recently made changes to their positions in the company. American Century Companies Inc. lifted its holdings in IDEXX Laboratories by 30.9% during the 4th quarter. American Century Companies Inc. now owns 809,814 shares of the company’s stock valued at $334,810,000 after buying an additional 191,385 shares in the last quarter. Mizuho Securities USA LLC lifted its holdings in IDEXX Laboratories by 45.4% during the 4th quarter. Mizuho Securities USA LLC now owns 7,761 shares of the company’s stock valued at $3,209,000 after buying an additional 2,424 shares in the last quarter. Quantbot Technologies LP lifted its holdings in IDEXX Laboratories by 1,870.5% during the 4th quarter. Quantbot Technologies LP now owns 13,301 shares of the company’s stock valued at $5,499,000 after buying an additional 12,626 shares in the last quarter. Lee Danner & Bass Inc. bought a new stake in IDEXX Laboratories during the 4th quarter valued at about $486,000. Finally, Blueshift Asset Management LLC bought a new stake in IDEXX Laboratories during the 4th quarter valued at about $521,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.1 %

NASDAQ IDXX opened at $420.99 on Monday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm has a market cap of $34.12 billion, a PE ratio of 39.46, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a 50 day moving average price of $437.36 and a 200 day moving average price of $444.76. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IDXX. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Piper Sandler lifted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, March 15th. Finally, Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.